エンパグリフロジンは,SIRT1/Akt/Nrf2経路を活性化することによって,三酸化アルゼンチンの誘発性腎臓毒性を軽減します
Chunrong Pang1, Wenlei Zhang1, Chenli Yue1
1Department of Pharmacy, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China, hrbmu.edu.cn.
Journal of toxicology
|February 16, 2026
まとめ
エンパグリフロジン (EMPA) は,酸化ストレスとアポトーシスを軽減することによって,三酸化アルゼン (ATO) 誘発性腎臓損傷を軽減します. APL治療におけるこの保護効果は,SIRT1/Akt/Nrf2経路の活性化を伴う.
科学分野:
- ネフロロジーはネフロロジーを用います.
- 薬理学 薬理学とは
- 腫瘍学 腫瘍学
背景:
- 三酸化物 (ATO) は,急性プロミエロサイト性白血病 (APL) の治療に不可欠です.
- ATOは腎臓に重大な毒性をもたらし,臨床応用を制限する.
- ATO誘発性腎臓毒性に対するエンパグリフロジン (EMPA) の保護効果は不明です.
研究 の 目的:
- ATO誘発性腎臓毒性を軽減するEMPAの可能性を調査する.
- EMPAの腎臓保護効果の根本的なメカニズムを探求する.
- 動物モデルと細胞モデルの両方でEMPAを評価する.
主な方法:
- ATOとEMPAで治療されたマウスの腎機能と腎臓構造の評価.
- HEK293T細胞における酸化ストレス,アポプトーシス,ミトコンドリア機能の評価.
- SIRT1/Akt/Nrf2経路とオートファギーの関与を調査した.
主要な成果:
- EMPAはマウスの腎機能を改善し,腎臓の構造的損傷を軽減しました.
- EMPAはATO誘発の酸化ストレスと細胞内のアポトーシスを抑制した.
- EMPAはミトコンドリア機能を保ち,オートファギーの機能不全を治療しました.
- EMPAはSIRT1/Akt/Nrf2経路を向上させました.
結論:
- EMPAは,ATO誘発性腎中毒性を改善する.
- 保護メカニズムには,SIRT1/Akt/Nrf2経路の活性化が含まれています.
- EMPAは酸化ストレスを抑制し,アポトーシスを減らし,ミトコンドリア機能を保護します.
関連する概念動画
01:23Dipeptidyl Peptidase 4 Inhibitors
729
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
729
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
696
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
696
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.2K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.6K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.6K
01:06Oral Hypoglycemic Agents: Glinides
700
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
700
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.6K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K